SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gains as its arm enters into commercial collaboration with BioQuiddity

01 Aug 2014 Evaluate

Cipla is currently trading at Rs. 457.45, up by 1.15 points or 0.25% from its previous closing of Rs. 456.30 on the BSE.

The scrip opened at Rs. 456.90 and has touched a high and low of Rs. 460.70 and Rs. 453.20 respectively. So far 32401 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 462.65 on 31-Jul-2014 and a 52 week low of Rs. 366.70 on 24-Feb-2014.

Last one week high and low of the scrip stood at Rs. 462.65 and Rs. 438.00 respectively. The current market cap of the company is Rs. 36781.83 crore.

The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 35.85% and 26.23% respectively.

Cipla’s 100% subsidiary - Cipla Europe NV has entered into a commercial collaboration with BioQuiddity Inc., covering the territory of the European Union and certain other European countries, for BioQuiddity’s OneDose ReadyfusOR in regional anesthetic applications for post-surgical pain management.

Cipla intends to launch the CE Marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this year. The ready-to-use infusion systems are non-electric, ambulatory, and should enable seamless transition between sites of care.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. 

Cipla Share Price

1238.15 -0.15 (-0.01%)
20-Apr-2026 11:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1237.75
Cipla 1238.15
Zydus Lifesciences 941.45
Lupin 2330.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×